Targeted Covalent Inhibitors for Drug Design
The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Abstract
In contrast to the traditional mechanism of drug action that relies on the reversible, noncovalent interaction of a ligand with its biological target, a targeted covalent inhibitor (TCI) is designed such that the initial, reversible association is followed by the formation of a covalent bond between an electrophile on the ligand and a nucleophilic center in the protein. Although this approach offers a variety of potential benefits (high potency and extended duration of action), concerns over the possible toxicological consequences of protein haptenization have hindered the development of the TCI concept. Recently, approaches to mitigate the risk of serious adverse reactions to this new class of agent have emerged, thus stimulating interest in the field and leading to authorization of the first cadre of TCIs to be marketed. The covalent inhibitor approach is rapidly gaining acceptance as a valuable tool in drug discovery, and is poised to make a major impact on the design of enzyme inhibitors and receptor modulators.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, the oxidation of drugs such as furosemide, isoniazid, acetaminophen, halothane, and model hepatotoxins via cytochrome P-450 can lead to hepatotoxic effects in animals and humans [131, 132].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [132]
Citations
Cites
The growing applications of click chemistry
Moses, J. E., & Moorhouse, A. D. (2007) · Chem. Soc. Rev. · doi:10.1039/b613014n · Cited by 2,367
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Self-citationCommon and Uncommon Cytochrome P450 Reactions Related to Metabolism and Chemical Toxicity
Guengerich, F. P. (2001) · Chemical Research in Toxicology · doi:10.1021/tx0002583 · Cited by 1,655
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases
Powers, J. C., Asgian, J. L., Ekici, Ö. D., & James, K. E. (2002) · Chemical Reviews · doi:10.1021/cr010182v · Cited by 1,090
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Kuhn, D. J., Chen, Q., Voorhees, P. M., Strader, J. S., Shenk, K. D., Sun, C. M., Demo, S. D., Bennett, M. K., van Leeuwen, F. W. B., Chanan-Khan, A. A., et al. (2007) · Blood · doi:10.1182/blood-2007-01-065888 · Cited by 768
Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., & Baillie, T. A. (2004) · Chemical Research in Toxicology · doi:10.1021/tx034170b · Cited by 706
Self-citationStepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., & Aleo, M. D. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200168d · Cited by 698
Self-citation
Research works printed but not linked: 7
- Parmar S., 2014, Pharm. Ther., 39, 483
- Johansson M. H., 2012, Mini-Rev. Med. Chem., 12, 1330
- Campuzano I. D. G., 2015, J. Biomol. Screening, 1
- Guerciolini R., 1997, Int. J. Obes., 21, 12
- Kumar S., 2008, Curr. Opin. Drug Discovery Dev., 11, 43
- Strelevitz T. J., 2015, Drug Metab. Rev., 47, 59
- The Wall Street Journal December 2 2015.
Cited by
Items 101–200 of 618
Oyedele, A.-Q. K., Ogunlana, A. T., Boyenle, I. D., Adeyemi, A. O., Temionu, O. R., Adelusi, T. I., Abdul-Hammed, M., Elegbeleye, O. E., & Odunitan, T. T. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10523-4 · Cited by 59
Reactivity of Covalent Fragments and Their Role in Fragment Based Drug Discovery
McAulay, K., Bilsland, A. E., & Bon, M. (2022) · Pharmaceuticals · doi:10.3390/ph15111366 · Cited by 60
An Easy, General and Practical Method for the Construction of Alkyl Sulfonyl Fluorides
Zhang, X., Fang, W., Lekkala, R., Tang, W., & Qin, H. (2020) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.202000515 · Cited by 55
Voice, A. T., Tresadern, G., Twidale, R. M., van Vlijmen, H., & Mulholland, A. J. (2021) · Chemical Science · doi:10.1039/d0sc06122k · Cited by 55
Peptide‐based covalent inhibitors of protein–protein interactions
Paulussen, F. M., & Grossmann, T. N. (2022) · Journal of Peptide Science · doi:10.1002/psc.3457 · Cited by 58
Designed covalent allosteric modulators: an emerging paradigm in drug discovery
Lu, S., & Zhang, J. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.013 · Cited by 55
Tri- and Tetrasubstituted Pyridinylimidazoles as Covalent Inhibitors of c-Jun N-Terminal Kinase 3
Muth, F., El‐Gokha, A., Ansideri, F., Eitel, M., Döring, E., Sievers‐Engler, A., Lange, A., Boeckler, F. M., Lämmerhofer, M., Koch, P., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01180 · Cited by 55
Ranking Reversible Covalent Drugs: From Free Energy Perturbation to Fragment Docking
Zhang, H., Jiang, W., Chatterjee, P., & Luo, Y. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00959 · Cited by 57
Zhou, H., Lü, J., Chinnaswamy, K., Stuckey, J. A., Liu, L., McEachern, D., Yang, C., Bernard, D., Shen, H., Rui, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22924-4 · Cited by 53
Biospecific Chemistry for Covalent Linking of Biomacromolecules
Cao, L., & Wang, L. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00066 · Cited by 53
Aryl Fluorosulfate Based Inhibitors That Covalently Target the SIRT5 Lysine Deacylase**
Bolding, J. E., Martín‐Gago, P., Rajabi, N., Gamon, L. F., Hansen, T. N., Bartling, C. R. O., Strømgaard, K., Davies, M. J., & Olsen, C. A. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202204565 · Cited by 53
Guardiola, S., Prades, R., Mendieta, L., Brouwer, A. J., Streefkerk, J., Nevola, L., Tarragó, T., Liskamp, R. M. J., & Giralt, E. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.04.013 · Cited by 53
Selenium Atom-Polarization Effect Determines TrxR-Specific Recognition of Metallodrugs
Chen, M., Cao, W., Wang, J., Cai, F., Zhu, L., Ma, L., & Chen, T. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c08802 · Cited by 53
Petri, L., Egyed, A., Bajusz, D., Imre, T., Hetényi, A., Martinek, T. A., Ábrányi‐Balogh, P., & Keserű, G. M. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112836 · Cited by 53
A covalent compound selectively inhibits RNA demethylase ALKBH5 rather than FTO
Lai, G., Li, Y., Zhu, H., Zhang, T., Gao, J., Zhou, H., & Yang, C. (2024) · RSC Chemical Biology · doi:10.1039/d3cb00230f · Cited by 53
Covalent Inhibitors: To Infinity and Beyond
Raouf, Y. S. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01308 · Cited by 50
The vinyl sulfone motif as a structural unit for novel drug design and discovery
Xiao, Y., & Chen, F. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2284201 · Cited by 49
Allimuthu, D., & Adams, D. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00424 · Cited by 49
Target Identification of Bioactive Covalently Acting Natural Products
Nomura, D. K., & Maimone, T. J. (2018) · Current topics in microbiology and immunology · doi:10.1007/82_2018_121 · Cited by 54
Multicomponent reaction–derived covalent inhibitor space
Sutanto, F., Shaabani, S., Neochoritis, C. G., Zarganes‐Tzitzikas, T., Patil, P., Ghonchepour, E., & Dömling, A. S. S. (2021) · Science Advances · doi:10.1126/sciadv.abd9307 · Cited by 51
BIreactive: A Machine-Learning Model to Estimate Covalent Warhead Reactivity
Palazzesi, F., Hermann, M. R., Grundl, M. A., Pautsch, A., Seeliger, D., Tautermann, C. S., & Weber, A. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b01058 · Cited by 49
The role of quantum chemistry in covalent inhibitor design
Mihalovits, L. M., Ferenczy, G. G., & Keserű, G. M. (2021) · International Journal of Quantum Chemistry · doi:10.1002/qua.26768 · Cited by 48
Advanced approaches of developing targeted covalent drugs
Gai, C., Harnor, S. J., Zhang, S., Cano, C., Zhuang, C., & Zhao, Q. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00216g · Cited by 47
From Concepts to Inhibitors: A Blueprint for Targeting Protein–Protein Interactions
Hong, S. H., Nguyễn, T. T., Ongkingco, J. F., Nazzaro, A., & Arora, P. S. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00046 · Cited by 46
Affinity and Selectivity Assessment of Covalent Inhibitors by Free Energy Calculations
Mihalovits, L. M., Ferenczy, G. G., & Keserű, G. M. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00834 · Cited by 47
Fragment-based drug design facilitates selective kinase inhibitor discovery
Wang, Z.-Z., Shi, X.-X., Huang, G.-Y., Hao, G., & Yang, G. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.04.001 · Cited by 49
Pei, H., Guo, W., Peng, Y., Xiong, H., & Chen, Y. (2022) · Medicinal Research Reviews · doi:10.1002/med.21886 · Cited by 46
Catalytic difluorocarbene insertion enables access to fluorinated oxetane isosteres
Tan, T., Zhou, F., Quirion, K. P., Wang, Y., Ng, D. Z. W., Luo, X., Chan, E. C. Y., Liu, P., & Koh, M. J. (2025) · Nature Chemistry · doi:10.1038/s41557-024-01730-7 · Cited by 44
Ding, Y., Li, D., Ding, C., Wang, P., Liu, Z., Wold, E. A., Ye, N., Chen, H., White, M. A., Shen, Q., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01514 · Cited by 45
Sui, Y., Ansari, M. F., & Zhou, C. (2021) · Chemistry - An Asian Journal · doi:10.1002/asia.202100146 · Cited by 44
Drug–Protein Adducts: Chemistry, Mechanisms of Toxicity, and Methods of Characterization
Gan, J., Zhang, H., & Humphreys, W. G. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00274 · Cited by 46
An updated patent review of anticancer Hsp90 inhibitors (2013-present)
Li, L., Chen, N., You, Q., & Xu, X. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1829595 · Cited by 44
Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting
Förster, M., Gehringer, M., & Laufer, S. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.07.079 · Cited by 43
Redenti, S., Marcovich, I., Vita, T. D., Pérez, C., Zorzi, R. D., Demitri, N., Pérez, D. I., Bottegoni, G., Bisignano, P., Bissaro, M., et al. (2018) · ChemMedChem · doi:10.1002/cmdc.201800778 · Cited by 44
Small molecule targeting of PTPs in cancer
Lazo, J. S., McQueeney, K. E., Burnett, J. C., Wipf, P., & Sharlow, E. R. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.09.011 · Cited by 43
The Nitro Group as a Masked Electrophile in Covalent Enzyme Inhibition
Ray, S., Kreitler, D. F., Gulick, A. M., & Murkin, A. S. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00225 · Cited by 42
Ureadepsipeptides as ClpP Activators
Griffith, E. C., Zhao, Y., Singh, A. P., Conlon, B. P., Tangallapally, R. P., Shadrick, W. R., Liu, J., Wallace, M. J., Yang, L., Elmore, J. M., et al. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00245 · Cited by 42
Wang, S., Faucher, F. F., Bertolini, M., Kim, H., Yu, B., Cao, L., Röltgen, K., Lovell, S., Shanker, V. R., Boyd, S. D., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c15843 · Cited by 42
A Fast Ab Initio Predictor Tool for Covalent Reactivity Estimation of Acrylamides
Palazzesi, F., Grundl, M. A., Pautsch, A., Weber, A., & Tautermann, C. S. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00316 · Cited by 42
Wang, Y., Dai, Y., Wu, X., Li, F., Liu, B., Li, C., Liu, Q., Zhou, Y., Bao, W., Zhu, M., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00510 · Cited by 43
Ma, Y., Li, L., He, S., Shang, C., Sun, Y., Liu, N., Meek, T. D., Wang, Y., & Shang, L. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00387 · Cited by 39
Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS
Roskoski, R. J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105806 · Cited by 41
Li, S., Zhang, P., Xu, F., Hu, S., Liu, J.-C., Tan, Y., Tu, Z., Sun, H., Zhang, Z., He, Q., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00272 · Cited by 40
Development of covalent NLRP3 inflammasome inhibitors: Chemistry and biological activity
Bertinaria, M., Gastaldi, S., Marini, E., & Giorgis, M. (2018) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2018.11.013 · Cited by 40
Selective Covalent Targeting of Mutated EGFR(T790M) with Chlorofluoroacetamide-Pyrimidines
Sato, M., Fuchida, H., Shindo, N., Kuwata, K., Tokunaga, K., Xiao-Lin, G., Inamori, R., Hosokawa, K., Watari, K., Shibata, T., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00574 · Cited by 41
Awoonor‐Williams, E., & Rowley, C. N. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00897 · Cited by 41
Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations
Tang, Y., Song, H., Wang, Z., Xiao, S., Xiang, X., Zhan, H., Wu, L., Wu, J., Xing, Y., Tan, Y., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110622 · Cited by 37
A practical guide for the assay-dependent characterisation of irreversible inhibitors
Mader, L. K., Borean, J. E., & Keillor, J. W. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00707g · Cited by 37
Covalent Targeting of Ras G12C by Rationally Designed Peptidomimetics
Yoo, D. Y., Hauser, A. D., Joy, S. T., Bar‐Sagi, D., & Arora, P. S. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00204 · Cited by 37
Udompholkul, P., Garza-Granados, A., Alboreggia, G., Baggio, C., McGuire, J. R., Pegan, S. D., & Pellecchia, M. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00467 · Cited by 40
CovBinderInPDB: A Structure-Based Covalent Binder Database
Guo, X.-K., & Zhang, Y. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01216 · Cited by 37
Acceptor-Controlled Transfer Dehydration of Amides to Nitriles
Okabe, H., Naraoka, A., Isogawa, T., Oishi, S., & Naka, H. (2019) · Organic Letters · doi:10.1021/acs.orglett.9b01657 · Cited by 36
Lipner, M. B., Peng, X. L., Jin, C., Xu, Y., Gao, Y., East, M. P., Rashid, N. U., Moffitt, R. A., Hererra, S. G., Morrison, A. B., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.129905 · Cited by 41
WIDOCK: a reactive docking protocol for virtual screening of covalent inhibitors
Scarpino, A., Petri, L., Knez, D., Imre, T., Ábrányi‐Balogh, P., Ferenczy, G. G., Gobec, S., & Keserű, G. M. (2021) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-020-00371-5 · Cited by 36
The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development
Yan, W., Zheng, Y., Dou, C. R., Zhang, G., Arnaout, T., & Cheng, W. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00106-y · Cited by 38
Targeted covalent inhibitors of MDM2 using electrophile-bearing stapled peptides
Charoenpattarapreeda, J., Tan, Y. S., Iegre, J., Walsh, S. J., Fowler, E., Eapen, R. S., Wu, Y., Sore, H. F., Verma, C. S., Itzhaki, L., et al. (2019) · Chemical Communications · doi:10.1039/c9cc04022f · Cited by 35
Arylfluorsulfat‐basierte Elektrophile für die kovalente Proteinmarkierung
Martín‐Gago, P., & Olsen, C. A. (2018) · Angewandte Chemie · doi:10.1002/ange.201806037 · Cited by 35
Covalent Inhibition Mechanism of Antidiabetic Drugs—Vildagliptin vs Saxagliptin
Wang, Y., Zhang, F., Diao, H., & Wu, R. (2019) · ACS Catalysis · doi:10.1021/acscatal.8b05051 · Cited by 35
Klein, P., Barthels, F., Johé, P., Wagner, A., Tenzer, S., Distler, U., Le, T. A., Schmid, P., Engel, V., Engels, B., et al. (2020) · Molecules · doi:10.3390/molecules25092064 · Cited by 35
Jukič, M., Janežič, D., & Bren, U. (2020) · Molecules · doi:10.3390/molecules25245808 · Cited by 37
Stilbene Boronic Acids Form a Covalent Bond with Human Transthyretin and Inhibit Its Aggregation
Smith, T. P., Windsor, I. W., Forest, K. T., & Raines, R. T. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00952 · Cited by 37
Covalent labeling of a chromatin reader domain using proximity-reactive cyclic peptides
Zhang, M. Y., Yang, H., Ortiz, G., Trnka, M. J., Petronikolou, N., Burlingame, A. L., DeGrado, W. F., & Fujimori, D. G. (2022) · Chemical Science · doi:10.1039/d2sc00555g · Cited by 34
Rational Design Strategies in DNA‐Encoded Libraries for Drug Discovery
Wang, X., Li, L., Shen, X., & Lu, X. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202511839 · Cited by 33
Characterization of covalent binding of tyrosine kinase inhibitors to plasma proteins
Liu, X., Feng, D., Zheng, M., Cui, Y., & Zhong, D. (2020) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2020.07.002 · Cited by 32
Gambini, L., Udompholkul, P., Salem, A. F., Baggio, C., & Pellecchia, M. (2020) · ChemMedChem · doi:10.1002/cmdc.202000355 · Cited by 32
Rocha, J., Santos, A., Gama, H., Moser, P. C., Falcão, A. C., Pressman, P., Hayes, A. W., & Soares-da-Silva, P. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2290 · Cited by 32
Suto, N., Kamoshita, S., Hosoya, S., & Sakurai, K. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202104347 · Cited by 32
Chen, D., Guo, D., Yan, Z., & Zhao, Y. (2017) · MedChemComm · doi:10.1039/c7md00571g · Cited by 32
Donnelly, D. P., Dowgiallo, M. G., Salisbury, J. P., Aluri, K. C., Iyengar, S. M., Chaudhari, M., Mathew, M., Miele, I., Auclair, J. R., Lopez, S. A., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b01136 · Cited by 32
Rood, J. J. M., Dormans, P. J. A., van Haren, M. J., Schellens, J. H. M., Beijnen, J. H., & Sparidans, R. W. (2018) · Journal of Chromatography B · doi:10.1016/j.jchromb.2018.05.011 · Cited by 31
Design and Characterization of an Intracellular Covalent Ligand for CC Chemokine Receptor 2
Zacarías, N. V. O., Chahal, K. K., Šimková, T., van der Horst, C., Zheng, Y., Inoue, A., Theunissen, E., Mallée, L., van der Es, D., Louvel, J., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01137 · Cited by 32
Tabuchi, Y., Yang, J., & Taki, M. (2021) · Chemical Communications · doi:10.1039/d0cc08109d · Cited by 31
Bonatto, V., Shamim, A., Rocho, F. D. R., Leitão, A., Luque, F. J., Lameira, J., & Montanari, C. A. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00515 · Cited by 32
Transglutaminase 2 as a therapeutic target for neurological conditions
Keillor, J. W., & Johnson, G. V. W. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1989410 · Cited by 31
Lysine Covalent Antagonists of Melanoma Inhibitors of Apoptosis Protein
Udompholkul, P., Baggio, C., Gambini, L., Alboreggia, G., & Pellecchia, M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01459 · Cited by 31
Wu, Y., & Brooks, C. L. (2022) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-022-00472-3 · Cited by 32
Advances in reversible covalent kinase inhibitors
Zhao, Z., & Bourne, P. E. (2024) · Medicinal Research Reviews · doi:10.1002/med.22084 · Cited by 29
Doornbos, M. L. J., Wang, X., Vermond, S. C., Peeters, L., Pérez‐Benito, L., Trabanco, A. A., Lavreysen, H., Cid, J. M., Heitman, L. H., Tresadern, G., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00051 · Cited by 28
Inhibitors of Immune Checkpoints: Small Molecule- and Peptide-Based Approaches
Fuchs, N. S., Zhang, L., Calvo‐Barreiro, L., Kuncewicz, K., & Gabr, M. T. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14010068 · Cited by 29
The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents
Coll-Martínez, B., Delgado, A., & Crosas, B. (2020) · Molecules · doi:10.3390/molecules25245956 · Cited by 28
Small Molecule-Based Enzyme Inhibitors in the Treatment of Primary Hyperoxalurias
Moya-Garzón, M. D., Gómez-Vidal, J. A., Alejo‐Armijo, A., Altarejos, J., Madoz, J. R. R., Fernandes, M. X., SALIDO, E. C., Salido, S., & Díaz‐Gavilán, M. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020074 · Cited by 31
Prioritisation of Compounds for 3CLpro Inhibitor Development on SARS-CoV-2 Variants
Jukič, M., Škrlj, B., Tomšič, G., Pleško, S., Podlipnik, Č., & Bren, U. (2021) · Molecules · doi:10.3390/molecules26103003 · Cited by 31
Benchmarking In Silico Tools for Cysteine p K a Prediction
Awoonor‐Williams, E., Golosov, A. A., & Horn̆ák, V. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00004 · Cited by 28
Structure–Reactivity Studies of 2-Sulfonylpyrimidines Allow Selective Protein Arylation
Pichon, M. M., Drelinkiewicz, D., Lozano, D., Moraru, R., Hayward, L. J., Jones, M., McCoy, M. A., Allstrum-Graves, S., Balourdas, D.-I., Joerger, A. C., et al. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00322 · Cited by 29
Hatmal, M. M., Abuyaman, O., & Taha, M. O. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.08.023 · Cited by 28
Discovery and optimization of selective RET inhibitors via scaffold hopping
Luo, Z., Wang, L., Fu, Z., Shuai, B., Luo, M., Hu, G., Chen, J., Sun, J., Wang, J., Li, J., et al. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128149 · Cited by 28
Klein, P., Johé, P., Wagner, A., Jung, S., Kühlborn, J., Barthels, F., Tenzer, S., Distler, U., Waigel, W., Engels, B., et al. (2020) · Molecules · doi:10.3390/molecules25061451 · Cited by 27
Extrahepatic metabolism of ibrutinib
Rood, J. J. M., Jamalpoor, A., van Hoppe, S., van Haren, M. J., Wasmann, R. E., Janssen, M. J., Schinkel, A. H., Masereeuw, R., Beijnen, J. H., & Sparidans, R. W. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00970-x · Cited by 27
Assessment of Tractable Cysteines for Covalent Targeting by Screening Covalent Fragments
Petri, L., Ábrányi‐Balogh, P., Imre, T., Pálfy, G., Perczel, A., Knez, D., Hrast, M., Gobec, M., Sosič, I., Nyíri, K., et al. (2020) · ChemBioChem · doi:10.1002/cbic.202000700 · Cited by 27
Chemical technologies for precise protein bioconjugation interfacing biology and medicine
Kumar, M., Reddy, N. C., & Rai, V. (2021) · Chemical Communications · doi:10.1039/d1cc02268g · Cited by 29
Combined Biophysical Chemistry Reveals a New Covalent Inhibitor with a Low-Reactivity Alkyl Halide
Li, T., Maltais, R., Poirier, D., & Lin, S. (2018) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.8b02225 · Cited by 27
Tran, Q. T. N., Tan, D. W. S., Wong, W. S. F., & Chai, C. L. L. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112481 · Cited by 26
Podoll, T., Pearson, P. G., Kaptein, A., Evarts, J., de Bruin, G., Hoek, M. E.-V., de Jong, A., van Lith, B., Sun, H., Byard, S. J., et al. (2022) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001116 · Cited by 28
Discovery of a novel covalent CDK4/6 inhibitor based on palbociclib scaffold
Shan, H., Ma, X., Yan, G., Luo, M., Zhong, X.-X., Lan, S., Yang, J., Liu, Y., Pu, C., Yu, T., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113432 · Cited by 25
Bruton tyrosine kinase inhibitors in multiple sclerosis: evidence and expectations
Krämer, J., & Wiendl, H. (2024) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001269 · Cited by 26
Fitting of kinact and KI Values from Endpoint Pre-incubation IC50 Data
Mader, L. K., & Keillor, J. W. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00054 · Cited by 25
Drug–protein adducts: past, present, and future
Baillie, T. A. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02567-8 · Cited by 25
Self-citationCovalent Kinase Inhibitors: An Overview
Gehringer, M. (2020) · Topics in medicinal chemistry · doi:10.1007/7355_2020_103 · Cited by 27
Huang, Y., Wei, L., Han, X., Chen, H., Ren, Y., Xu, Y., Song, R., Rao, L., Chen, S., Peng, C., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111749 · Cited by 24
Design and SAR Analysis of Covalent Inhibitors Driven by Hybrid QM/MM Simulations
Lodola, A., Callegari, D., Scalvini, L., Rivara, S., & Mor, M. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0282-9_19 · Cited by 25
Metadata
- Authors
- Baillie, T. A.
- Affiliations
- University of Washington (US)
- Corresponding author
- Baillie, Thomas A.
- ORCID
- Baillie, Thomas A.
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2016-08-19
- Volume
- 55
- Issue
- 43
- Pages
- 13408-13421
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- OpenAlex
- W2517550655
- Cited by
- 578
- References
- 118
- Citations by year
- 2026: 55 · 2025: 77 · 2024: 66 · 2023: 46 · 2022: 49 · 2021: 76 · 2020: 72 · 2019: 52 · 2018: 46 · 2017: 31 · 2016: 5
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Angewandte Chemie International Edition (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- targeted covalent inhibitors, covalent drug design, drug toxicity, enzyme inhibitors, receptor modulators, drug discovery, non-covalent binding
- MeSH terms
- Animals, Enzyme Inhibitors, Humans, Ligands, Protein Kinases, Drug Design, Molecular Structure, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.